CCHT(SZ:000661) Zheng Quan Shi Bao Wang·2025-09-08 11:03Core Viewpoint - Changchun High-tech has received approval for the clinical trial application of its self-developed oral growth hormone secretagogue, GS3-007a, aimed at treating pediatric growth hormone deficiency (PGHD) [1][2] Group 1: Product Development - GS3-007a is classified as a Class 1 chemical drug and is designed for children with PGHD, a common endocrine disorder leading to stunted growth [1] - The incidence of PGHD in China is approximately 1 in 8600, with around 510 million children affected by short stature, and about 230,000 diagnosed cases [1] - The product offers an alternative to existing treatments, which require subcutaneous injections, by providing a daily oral administration option [2] Group 2: Strategic Alignment - The development of GS3-007a aligns with the company's strategic focus on pediatric growth and development products, addressing unmet clinical needs in this area [2] - There are currently no similar products available in the domestic market, indicating a potential competitive advantage for the company [2] Group 3: Recent Developments - Changchun High-tech has recently announced multiple approvals for clinical trial applications from its subsidiary, Jinsai Pharmaceutical, including other innovative drug candidates [3] - The company has also received FDA approval for a hypertension treatment, showcasing its expanding product portfolio [3][4]